Eric M Bachman is a Founder of Invisible Economics at Invisible Economics. Colleagues describe him as "Eric is a driven, dedicated, and knowledgeable pricing and market access consultant. He inspires his team to rise to client's challenges, and deliver results to the best of their ability. His expertise and people skills make him an excellent mentor. Eric is an asset as a manager, a team leader, and as a colleague.", "Eric is one of the hardest working colleagues that I have had the pleasure of working with. Over the many years, Eric has established himself as a respected and trusted adviser to numerous pharmaceutical companies and is constantly called by industry executives to provide input on global pricing & market access concerns. Eric has also established himself as an expert in rare and orphan diseases having interviewed more global rare disease specialists than any other consultant that I have worked with. Eric’s rare disease expertise and his vast understanding of the global payer segments has resulted in collaborations with numerous pharmaceutical manufacturers and his insights have been relied upon for multiple global pricing strategies and M&A opportunity assessments. Overall, it’s always a true pleasure working with Eric. His enthusiasm, passion, and drive to achieve the projects objectives have been noted by numerous clients and he is always recommended by industry and consulting peers. Eric comes with my highest recommendation!", and "Eric consistently demonstrates a high level of commitment to his client’s objectives, and is truly passionate about helping clients achieve their commercial goals. He is extremely diligent with respect to uncovering and articulating value propositions for pharmaceuticals, and is never cynical or complacent about the potential for new drugs to deliver meaningful results to payers, physicians and patients. On project teams where we worked together, clients often commented to me that Eric’s enthusiasm for their therapies had inspired re-engaged and creative thinking around how to formulate the value proposition and ensure commensurate levels of pricing and access. Eric is particularly energetic and inspired by therapies for rare and orphan diseases, and always sees the big picture of how pricing and access translate into funding for further innovation; for this reason, he is particularly skilled at thinking through portfolio and pipeline considerations. In addition, Eric is a self-starter who pushes his colleagues to improve work processes and quality delivery. I enjoyed working with Eric and am confident that he will have a successful career in the biopharmaceutical industry."